Market Access In Germany After AMNOG Major Healthcare Reform Web Forum 13th Oct 2011
The virtual conference will provide an occasion for meeting all C-level Executives EVPs, SVPs,VPs, Directors, Managers and Analysts involved with market access and will allow the formation of new partnerships.
Germany has been, from a business perspective, a very attractive market for innovative drugs and biotechnology. Until last year, the German Healthcare system used a free-market pricing system where pharmaceutical companies were able to set the prices for their drugs and sickness funds would reimburse drugs regardless of their price.
With the passing of the legislation entitled "Act on the reorganization of the pharmaceutical market in the public health insurance" (AMNOG), a reform is underway that is revolutionizing reimbursement for pharmaceuticals in Germany. Biotechnology and pharmaceutical companies that are currently developing products will need to take into account a "fourth hurdle". On top of demonstrating quality, safety and efficacy, they will also have to demonstrate an additional clinical benefit over the standard therapy.
AMNOG legislation will definitely result in substantial changes in the biggest pharmaceutical market in Europe. Therefore, potential delays with the new requirements could mean severe losses for pharmaceutical companies looking to introduce new products. Moreover, Since August 2010, drug manufacturers have been burdened by compulsory rebates, which are already 1.2 billion euros. This is expected to increase to 2 billion euros per year.
AMNOG has raised several questions regarding new processes and guidelines that will have to be addressed and clarified. Kakushin Group is offering an invaluable opportunity to discuss the most relevant details and repercussions of Germany's recent health care reform with policy makers and other key opinion leaders from industry.
Without this critical information, executives will lack the tools necessary to effectively manage the conflicting incentives of all parties involved and they will struggle under the administrative burden commonly associated with these changes in the regulations. Attend this online training and improve your pricing and reimbursement strategy; secure pharmaceutical market access for your innovative drug in one of the most powerful markets worldwide.
Organized by: Kakushin Group